Purified Recombinant Human TRAIL (Accession # P50591)
<0.1 EU/µg as determined by the LAL method
This monoclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.3 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.
Storage and Handling
The lyophilized antibody can be stored desiccated at -20°C to -70°C for up to twelve months. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months.
Country of Origin
Other Applications Reported In Literature ?
IHC (NBF/Par.): This antibody should give satisfactory staining results when used at a concentration of 25 µg/ml. The recommended secondary antibody for IHC is PN:M114. For chromogenic detection with high signal and low background use PN:D100 or PN:K107.
Neutralization: This antibody is useful for neutralization of Human TRAIL bioactivity. The antibody dose required to neutralize 50% (ND50) of the biological activity of Human TRAIL (at 12 ng/ml) is 2-8 µg/ml.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Mouse Anti-Human TNF-Related Apoptosis-Inducing Ligand (TRAIL) (Clone 75411) recognizes an epitope on Human TRAIL. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
TNF-related apoptosis-inducing ligand (TRAIL) belongs to the tumor necrosis factor family and activates rapid apoptosis in tumor cells, and binds to the death-signaling receptor DR4.1 TRAIL is a potential tumor specific cancer therapeutic agent, since it selectively induces apoptosis in transformed versus normal cells.2
References & Citations
1. Ashkenazi, A. et al. (1997) Science 227: 818
2. Romeo, G. et al. (2005) Current Pharmaceutical Design 11: 933
Products are for research use only. Not for use in diagnostic or therapeutic procedures.